Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Clicks: 1
ID: 304820
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #449 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. Vancomycin treatment failure in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is not uncommon, even when MRSA is susceptible to vancomycin. The aim of our study was to evaluate whether vancomycin minimum inhibitory concentration has any influence on the mortality associated with MRSA bacteremia. Methods. A total of 414 episodes of MRSA bacteremia were prospectively followed-up from 1991 through 2005. MIC of vancomycin for the first isolate was determined by E-test. Clinical variables recorded were age, comorbidity, prior administration of vancomycin, use of corticosteroids, prognosis of underlying disease, source of bacteremia, the need for mechanical ventilation, shock, and mortality. A “treatment group” variable was created and defined as follows: (1) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1 µg/mL (38 episodes), (2) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1.5 µg/mL (90 episodes), (3) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 µg/mL (40 episodes), and (4) receipt of inappropriate empirical therapy (246 episodes). Univariate and multivariate analyses were performed. Results. Episodes caused by strains with a vancomycin MIC of 2 µg/mL were independently associated with a lower risk of shock (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.15–0.75). Multivariate analysis selected receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 µg/mL (OR, 6.39; 95% CI, 1.68–24.3), receipt of inappropriate empirical therapy (OR, 3.62; 95% CI, 1.20–10.9), increasing age (OR, 1.02; 95% CI, 1.00–1.04), use of corticosteroids (OR, 1.85; 95% CI, 1.04–3.29), an ultimately (OR, 10.2; 95% CI, 2.85–36.8) or rapidly (OR, 1.81; 95% CI, 1.06–3.10) fatal underlying disease, high-risk (OR, 3.60; 95% CI, 1.89–6.88) and intermediate-risk (OR, 2.18; 95% CI, 1.17–4.04) sources of bacteremia, and shock (OR, 7.38; 95% CI, 4.11–13.3) as the best predictors of mortality. Conclusions. Mortality associated with MRSA bacteremia was significantly higher when the empirical antibiotic was inappropriate and when vancomycin was empirically used for treatment of infection with strains with a high vancomycin MIC (>1 µg/mL).
| Reference Key |
openalex_W2114585210
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Álex Soriano, Francesc Marco, J. A. Martínez, E. Pisos, Manel Almela, V Dimova, D. Alamo, M. Mar Bernal, J. Marey López, José Mensa |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Year | 2007 |
| DOI |
10.1086/524667
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.